Century Therapeutics Appoints Chief Scientific Officer, Finance Chief

MT Newswires Live

2024/09/26

Century Therapeutics (IPSC) said Thursday it appointed Chad Cowan chief scientific officer, effective Oct. 1, and Morgan Conn chief financial officer, effective Oct. 14.

Cowan previously served as an executive scientific adviser of the company, following the acquisition of Clade Therapeutics in April 2024, where he was founder and CEO.

Meanwhile, Conn was the chief business officer at Pharvaris prior to joining Century.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2470338177"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2470338177\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2470338177?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-26 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2470338177","market":"sg","top_or_hot":-1,"title":"Century Therapeutics Appoints Chief Scientific Officer, Finance Chief","media":"MT Newswires Live","content":"<html><body><p> Century <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (IPSC) said Thursday it appointed Chad Cowan chief scientific officer, effective Oct. 1, and Morgan Conn chief financial officer, effective Oct. 14.</p><p>Cowan previously served as an executive scientific adviser of the company, following the acquisition of Clade Therapeutics in April 2024, where he was founder and CEO.</p><p>Meanwhile, Conn was the chief business officer at Pharvaris prior to joining Century.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Century Therapeutics Appoints Chief Scientific Officer, Finance Chief</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCentury Therapeutics Appoints Chief Scientific Officer, Finance Chief\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-09-26 20:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Century <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (IPSC) said Thursday it appointed Chad Cowan chief scientific officer, effective Oct. 1, and Morgan Conn chief financial officer, effective Oct. 14.</p><p>Cowan previously served as an executive scientific adviser of the company, following the acquisition of Clade Therapeutics in April 2024, where he was founder and CEO.</p><p>Meanwhile, Conn was the chief business officer at Pharvaris prior to joining Century.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPSC","symbol_name":"Century Therapeutics, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2470338177","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2470338177","pubTimestamp":1727353881,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Century Therapeutics  said Thursday it appointed Chad Cowan chief scientific officer, effective Oct. 1, and Morgan Conn chief financial officer, effective Oct. 14.Cowan previously served as an executive scientific adviser of the company, following the acquisition of Clade Therapeutics in April 2024, where he was founder and CEO.Meanwhile, Conn was the chief business officer at Pharvaris prior to joining Century.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IPSC":"Century Therapeutics, Inc.","LENZ":"Therapeutics","BK4539":"次新股","BK4505":"高瓴资本持仓","BK4139":"生物科技","CNBKA":"世纪银行"},"translate_title":"Century Therapeutics任命首席科学官、财务主管","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNBKA":1,"LENZ":1,"IPSC":1},"content_text":"Century Therapeutics (IPSC) said Thursday it appointed Chad Cowan chief scientific officer, effective Oct. 1, and Morgan Conn chief financial officer, effective Oct. 14.Cowan previously served as an executive scientific adviser of the company, following the acquisition of Clade Therapeutics in April 2024, where he was founder and CEO.Meanwhile, Conn was the chief business officer at Pharvaris prior to joining Century.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}